Artiva Biotherapeutics Receives the US FDA’s Fast Track Designation for AlloNK (AB-101) to Treat Lupus Nephritis
Shots:
- The company received the US FDA’s FTD for AlloNK (AB-101) + rituximab or obinutuzumab for the treatment of lupus nephritis (LN)
- Earlier in Aug 2023, the US FDA cleared the IND application for AlloNK + rituximab to initiate the clinical evaluation of LN patients who have relapsed or did not receive previous SoC treatment
- AlloNK, an allogeneic NK cell therapy, functions by enhancing the ADCC effect of mAb or NK cell engagers. The P-I study primarily investigates the safety, tolerability & preliminary activity of AlloNK + rituximab among LN patients (n=18). Additionally, the company is evaluating the safety & efficacy of AlloNK + rituximab in a P-I/II study for treating r/r B-NHL patients
Ref: Artiva Biotherapeutics | Image: Artiva Biotherapeutics
Related News:- ImmPACT Bio’ IMPT-514 Receives the US FDA’s Fast Track Designation for Refractory Lupus Nephritis and Systemic Lupus Erythematosus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
